Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ranibizumab biosimilar - Xbrane

Next Previous
Drug Profile

Ranibizumab biosimilar - Xbrane

Alternative Names: Lucamzi; VA-2; Ximluci; Xlucane

Latest Information Update: 10 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xbrane
  • Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Choroidal neovascularisation; Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion; Wet age-related macular degeneration
  • Preregistration Degenerative myopia; Retinal oedema

Most Recent Events

  • 10 Dec 2025 Ximluci® is still in reg phase for wet age-related macular degeneration, diabetic macular oedema, diabetic retinopathy, retinal vein occlusion, choroidal neovascularisation in EU, Norway, Iceland and Liechtenstein (Xbrane website, December 2025)
  • 10 Nov 2025 Launched for Choroidal neovascularisation in Norway (Intravitreous)
  • 10 Nov 2025 Launched for Diabetic macular oedema in Norway (Intravitreous)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top